Avivagen Inc. announced the appointments of Mr. Kym Anthony to the position of C.E.O. and Mr. Jeffrey Kraws, a director of the Corporation, to the position of Chairman of the Board. Mr. Anthony previously held the dual role of interim C.E.O. and Chairman. In light of Mr. Anthony's appointment as Avivagen's permanent C.E.O. he has stepped down as Chairman but will remain on the board.

Mr. Kraws is currently CEO of Crystal Research Associates and partner at CRA Advisors. Previously Mr. Kraws served as co-president of The Investor Relations Group (IRG); managing director of healthcare research for Ryan Beck & Co.; and director of research/senior pharmaceutical analyst and managing director at Gruntal & Company. In addition to serving as CEO of Crystal Research Associates, Mr. Kraws is currently chairman of Synthetic Biologics Inc., president of Ra Medical Systems and an Industry Advisor in healthcare investment banking for Piper Jaffray.

Through his years of experience, Mr. Kraws has cultivated a wealth of industry knowledge and a level of credible, insightful equity analysis that few share. As a result, he has provided guest commentary for many network news programs, including Bloomberg, FOX Business, and CNBC, among others, and has become a valuable resource for financial journalists from the New York Times, Forbes, Bloomberg, CBS MarketWatch, and MedAdNews, among other publications.